Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 201–300 of 1,001
ACE inhibitors and ARBs: Managing potassium and renal function
Momoniat, T., Ilyas, D., & Bhandari, S. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18024 · Cited by 98
Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 107
Hypertension in chronic kidney disease—treatment standard 2023
Georgianos, P. I., & Agarwal, R. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad118 · Cited by 116
Mima, A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.04.011 · Cited by 94
Acute Kidney Injury: A Bona Fide Complication of Diabetes
Advani, A. (2020) · Diabetes · doi:10.2337/db20-0604 · Cited by 93
Kolkhof, P., Joseph, A., & Kintscher, U. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105859 · Cited by 94
Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
McGrath, K. L., & Edi, R. (2019) · PubMed · Cited by 127
Fiend and friend in the renin angiotensin system: An insight on acute kidney injury
Sharma, N., Anders, H., & Gaikwad, A. B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.018 · Cited by 93
Therapeutic Insights in Chronic Kidney Disease Progression
Shabaka, A., Cases‐Corona, C., & Juarez, G. M. F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.645187 · Cited by 96
Tian, N., Gao, Y., Wang, X., Wu, X., Zou, D., Zhu, Z., Han, Z., Wang, T., & Shi, Y. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s167405 · Cited by 87
Cardiovascular Disease in Diabetes and Chronic Kidney Disease
Swamy, S., Noor, S. M., & Mathew, R. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226984 · Cited by 96
Heerspink, H. J. L., Andress, D. L., Bakris, G. L., Brennan, J. J., Correa‐Rotter, R., Dey, J., Hou, F. F., Kitzman, D. W., Kohan, D. E., Makino, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13245 · Cited by 90
Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
Georgianos, P. I., & Agarwal, R. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.027 · Cited by 87
Judge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R. J., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae263 · Cited by 91
Improvements in the Management of Diabetic Nephropathy
Dounousi, E. C., Duni, Α., Leivaditis, K., Vaios, V., Eleftheriadis, T., & Liakopoulos, V. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.119 · Cited by 89
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
An Update on the Use of Animal Models in Diabetic Nephropathy Research
Betz, B. B., & Conway, B. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0706-2 · Cited by 88
Inhibition of RAS in diabetic nephropathy
Campbell, K., & Yacoub, R. (2015) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s37893 · Cited by 81
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Lipid, blood pressure and kidney update 2013
Banach, M., Serban, C., Aronow, W. S., Rysz, J., Dragan, S., Lerma, E. V., Apetrii, M., & Covic, A. (2014) · International Urology and Nephrology · doi:10.1007/s11255-014-0657-6 · Cited by 73
Application of new acute kidney injury biomarkers in human randomized controlled trials
Parikh, C. R., Moledina, D. G., Coca, S. G., Thiessen‐Philbrook, H., & Garg, A. X. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.027 · Cited by 78
Roddick, A., Wonnacott, A., Webb, D. R., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03339-3 · Cited by 93
Revisiting RAAS blockade in CKD with newer potassium-binding drugs
Georgianos, P. I., & Agarwal, R. (2017) · Kidney International · doi:10.1016/j.kint.2017.08.038 · Cited by 79
Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease
Humalda, J. K., & Navis, G. J. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000073 · Cited by 84
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy
Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 79
Hypertension and diabetes mellitus: highlights of a complex relationship
Yildiz, M., Esenboğa, K., & Oktay, A. A. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000748 · Cited by 94
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Ix, J. H., Pecoits‐Filho, R., Perkovic, V., Sarnak, M. J., Tobe, S. W., Tomson, C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.025 · Cited by 81
Self-citationWnt/β-catenin signaling and renin–angiotensin system in chronic kidney disease
Zhou, L., & Liu, Y. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000205 · Cited by 74
From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options
Sharma, S., & Smyth, B. J. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000516911 · Cited by 87
Souza, A. C. P., Bocharov, A. V., Baranova, I. N., Vishnyakova, T. G., Huang, Y. G., Wilkins, K. J., Hu, X., Street, J. M., Álvarez-Prats, A., Mullick, A. E., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.043 · Cited by 77
Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes
Kim, S. S., Kim, J. H., & Kim, I. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.245 · Cited by 86
Cardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 78
Schievink, B., Kröpelin, T., Mulder, S., Parving, H. ‐., Remuzzi, G., Dwyer, J., Vemer, P., de Zeeuw, D., & Lambers Heerspink, H. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12583 · Cited by 72
Ghazi, L., & Drawz, P. E. (2017) · F1000Research · doi:10.12688/f1000research.9692.1 · Cited by 81
Management of hypertension in chronic kidney disease
Townsend, R. R., & Taler, S. J. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.114 · Cited by 79
Prevalence and Management of Diabetic Nephropathy in Western Countries
Satirapoj, B., & Adler, S. G. (2015) · Kidney Diseases · doi:10.1159/000382028 · Cited by 80
Anti-fibrotic treatments: A review of clinical evidence
Allinovi, M., De Chiara, L., Angelotti, M. L., Becherucci, F., & Romagnani, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.017 · Cited by 68
Leoncini, G., Viazzi, F. C., Cosmo, S. D., Russo, G. T., Fioretto, P., & Pontremoli, R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00803-3 · Cited by 77
Perez-Gomez, M., Sanchez-Niño, M., Sanz, A., Martín-Cleary, C., Ruiz-Ortega, M., Egido, J., Navarro-González, J., Ortiz, A., & Fernandez-Fernandez, B. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4061325 · Cited by 68
Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease
Yamout, H., Lazich, I., & Bakris, G. L. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.005 · Cited by 74
The Effects of 2′- O -Methoxyethyl Oligonucleotides on Renal Function in Humans
Crooke, S. T., Baker, B. F., Pham, N. C., Hughes, S. G., Kwoh, T. J., Cai, D., Tsimikas, S., Geary, R. S., & Bhanot, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0693 · Cited by 70
The Prevalence and Management of Diabetic Nephropathy in Asia
Tomino, Y., & Gohda, T. (2015) · Kidney Diseases · doi:10.1159/000381757 · Cited by 68
D’Elia, L., Rossi, G., di Cola, M. S., Savino, I. G., Galletti, F., & Strazzullo, P. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09110914 · Cited by 68
Developing Treatments for Chronic Kidney Disease in the 21st Century
Breyer, M. D., & Suszták, K. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.08.001 · Cited by 73
Sakata, Y., Shiba, N., TAKAHASHI, J. C., Miyata, S., Nochioka, K., Miura, M., Takada, T., Saga, C., Shinozaki, T., Sugi, M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu504 · Cited by 75
Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management
Hundemer, G. L., & Sood, M. M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105835 · Cited by 73
50 years forward: mechanisms of hyperglycaemia-driven diabetic complications
Russell, N., & Cooper, M. E. (2015) · Diabetologia · doi:10.1007/s00125-015-3600-1 · Cited by 80
Herrington, W. G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L. H., Dendale, P., Seferovic, P., Rosano, G., Staplin, N., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2286 · Cited by 63
Contemporary review of IgA nephropathy
Filippone, E. J., Gulati, R., & Farber, J. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436923 · Cited by 72
Coca, S. G., Zabetian, A., Ferket, B. S., Zhou, J., Testani, J. M., Garg, A. X., & Parikh, C. R. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060642 · Cited by 66
Donate‐Correa, J., Tagua, V. G., Ferri, C. M., Martín‐Núñez, E., Hernández-Carballo, C., Ureña, P., Ruiz‐Ortega, M., Ortíz, A., Fernández, C. M., & Navarro‐González, J. F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030287 · Cited by 69
Bramlage, P., Lanzinger, S., van Mark, G., Hess, E., Fahrner, S., Heyer, C. H. J., Friebe, M., Seufert, J., Danne, T., & Holl, R. W. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0837-x · Cited by 65
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy
Scheele, W., Diamond, S., Gale, J., Clerin, V., Tamimi, N., Le, V., Walley, R., Grover-Páez, F., Perros-Huguet, C., Rolph, T., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050473 · Cited by 65
Trensz, F., Bortolamiol, C., Kramberg, M., Wanner, D., Hadana, H., Rey, M., Strasser, D. S., Delahaye, S., Hess, P., Vezzali, E., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253864 · Cited by 65
De Novo Glomerular Diseases after Renal Transplantation
Ponticelli, C. E., Moroni, G. L., & Glassock, R. J. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12571213 · Cited by 64
Ortiz, A., Ferro, C. J., Balafa, O., Burnier, M., Ekart, R., Halimi, J.-M., Kreutz, R., Mark, P. B., Persu, A., Rossignol, P., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab167 · Cited by 62
Combination drug treatment in hypertension
Tsioufis, C. P., & Thomopoulos, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.011 · Cited by 65
Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease
Provenzano, M., Rotundo, S., Chiodini, P., Gagliardi, I., Michael, A., Angotti, E., Borrelli, S., Serra, R., FOTI, D. P., Sarro, G. D., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165846 · Cited by 69
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial
Leehey, D. J., Zhang, J. H., Emanuele, N. V., Whaley-Connell, A., Palevsky, P. M., Reilly, R. F., Guarino, P., & Fried, L. F. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02850315 · Cited by 62
Self-citationSun, J. M., Huang, X., Niu, C., Wang, X., Li, W., Liu, M., Wang, Y., Huang, S., Chen, X., Li, X., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101811 · Cited by 65
Alcocer, L. A., Bryce, A., Brasil, D., Lara-Terán, J. J., Cortes, J. M., Quesada, D., & Rodriguez, P. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00605-5 · Cited by 71
Hofherr, A., Williams, J. H., Gan, L., Söderberg, M. P., Hansen, P., & Woollard, K. J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02794-8 · Cited by 62
Hyperkalemia in chronic kidney disease
Watanabe, R. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.s1.31 · Cited by 60
Diabetic nephropathy: A twisted thread to unravel
Dagar, N., Das, P., Bisht, P., Taraphdar, A. K., Ravichandiran, V., & Arumugam, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119635 · Cited by 60
Goupil, R., Tsuyuki, R. T., Santesso, N., Terenzi, K. A., Habert, J., Cheng, G., Gysel, S. C., Bruneau, J., Leung, A. A., Campbell, N. R. C., et al. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241770 · Cited by 60
Peng, L., Chen, Y., Shi, S., & Wen, H. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02696-w · Cited by 61
Heerspink, H. J. L., Ninomiya, T., Persson, F., Brenner, B. M., Brunel, P., Chaturvedi, N., Desai, A. S., Haffner, S. M., Mcmurray, J. J. V., Solomon, S. D., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12600 · Cited by 57
Epidemiology of hyperkalemia: an update
Kovesdy, C. P. (2016) · Kidney International Supplements · doi:10.1016/j.kisu.2016.01.002 · Cited by 68
Should we eat more potassium to better control blood pressure in hypertension?
Burnier, M. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx340 · Cited by 63
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
EMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.007 · Cited by 57
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Serban, M.-C., Rysz, J., Voroneanu, L., & Covic, A. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 56
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Valdivielso, J. M., Balafa, O. C., Ekart, R., Ferro, C. J., Mallamaci, F., Mark, P. B., Rossignol, P., Sarafidis, P. A., Vecchio, L. D., & Ortíz, A. (2021) · Drugs · doi:10.1007/s40265-021-01555-5 · Cited by 62
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Lin, H., Geurts, F., Hassler, L., BATLLE, D. C., Colafella, K. M. M., Denton, K. M., Zhuo, J. L., Li, X. C., Ramkumar, N., Koizumi, M., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000236 · Cited by 60
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 55
EMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, C. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.012 · Cited by 74
Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes
Lovshin, J. A., Boulet, G., Lytvyn, Y., Lovblom, L. E., Bjornstad, P., Farooqi, M. A., Lai, V., Cham, L., Tse, J., Orszag, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96968 · Cited by 56
Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials
Badve, S. V., Palmer, S. C., Hawley, C. M., Pascoe, E. M., Strippoli, G. F., & Johnson, D. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv269 · Cited by 60
Recent advances in managing and understanding diabetic nephropathy
Tang, S. C. W., Chan, G. C. W., & Lai, K. N. (2016) · F1000Research · doi:10.12688/f1000research.7693.1 · Cited by 63
Huang, Y. M., Xu, D., Long, J., Shi, Y., Zhang, L., Wang, H., Levin, A., & Zhao, M. (2018) · Nephrology · doi:10.1111/nep.13489 · Cited by 57
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 67
Renin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
Ksiazek, S. H., Hu, L., Andò, S., Pirklbauer, M., Säemann, M. D., Ruotolo, C., Zaza, G., Manna, G. L., Nicola, L. D., Mayer, G. J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074035 · Cited by 66
Feng, B., Meng, R., Huang, B., Bi, Y., Shen, S., & Zhu, D. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.06.009 · Cited by 56
Stephens, J. W., Brown, K. E., & Min, T. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13942 · Cited by 61
Diabetes and chronic kidney disease
Kowalski, A., Krikorian, A., & Lerma, E. V. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.07.002 · Cited by 57
Feng, Y., Huang, R., Kavanagh, J., Li, L., Zeng, X., Li, Y., & Fu, P. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00321-5 · Cited by 53
Ku, E., McCulloch, C. E., Vittinghoff, E., Lin, F., & Johansen, K. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009992 · Cited by 55
Sánchez, J. J. G., Thompson, J. C., Scott, D. A., Evans, R., Rao, N., Sörstadius, E., James, G., NOLAN, S. T., Wittbrodt, E. T., Sultan, A. A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02006-z · Cited by 64
Drawz, P. E., Beddhu, S., Bignall, O. N. R., Cohen, J. B., Flynn, J. T., Ku, E., Rahman, M., Thomas, G., Weir, M. R., & Whelton, P. K. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.013 · Cited by 57
Drug treatment of hypertension in Sweden in relation to sex, age, and comorbidity
Wallentin, F., Wettermark, B., & Kahan, T. (2018) · The Journal of Clinical Hypertension · doi:10.1111/jch.13149 · Cited by 50
Sávio-Silva, C., Beyerstedt, S., Soinski-Sousa, P. E., Casaro, E. B., Balby-Rocha, M. T. A., Simplício-Filho, A., Alves-Silva, J., & Rangel, É. B. (2020) · Stem Cells International · doi:10.1155/2020/8833725 · Cited by 57
Hyperkalemia: Prevalence, Predictors and Emerging Treatments
Larivée, N., Michaud, J. B., More, K. M., Wilson, J.-A. S., & Tennankore, K. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00289-z · Cited by 60
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 65
Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions
Roointan, A., Xu, R., Corrie, S. R., Hagemeyer, C. E., & Alt, K. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000608 · Cited by 60
Gale, J. D., Gilbert, S., Blumenthal, S., Elliott, T., Pergola, P. E., Goteti, K., Scheele, W., & Perros-Huguet, C. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.07.010 · Cited by 50
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 48
Slowing progression of chronic kidney disease
Drawz, P. E., & Rosenberg, M. E. (2013) · Kidney International Supplements · doi:10.1038/kisup.2013.80 · Cited by 65
SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
Piperidou, A., Loutradis, C., & Sarafidis, P. A. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00393-4 · Cited by 51
López-Jaramillo, P. A., López-López, J., Lopez-Lopez, C., & Rodriguez-Alvarez, M. I. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-31 · Cited by 52
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.